Skip to content
lifestyle.brownplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oshyn
Oshyn Releases 2026 Digital Trust Index: Enterprises Have Improved Their Reliability, but Gaps Remain
July 28, 2026
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
July 20, 2026
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
July 13, 2026
Oshyn Launches MCP Server, Bringing No-Cost DXP Strategy Tools Directly to AI Assistants
July 7, 2026
Oshyn Launches Suite of Digital Strategy Tools to Aid in DXP Projects and Platform Reliability
June 23, 2026
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
June 16, 2026
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
June 2, 2026
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
June 1, 2026
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
May 26, 2026
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
May 5, 2026
1
2
Next Page
→